Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of androgenetic alopecia (male pattern baldness) in men,Off-label: female pattern hair loss, alopecia areata, chemotherapy-induced alopecia, beard enhancement
Mild to moderate pain,Pain accompanied by fever
Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
About 20% bound to plasma proteins (primarily albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Approximately 3-4 L/kg, indicating extensive distribution into tissues.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 75%.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
None
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis,Hypotension: can occur if applied to broken skin or excessive application,Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis),Cardiac: avoid in patients with known coronary artery disease or arrhythmias
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to minoxidil or any component of the formulation,Concurrent use with other topical hair growth products
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No significant food interactions. Avoid excessive alcohol intake as it may worsen orthostatic hypotension if systemic absorption occurs.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No specific dose adjustment guidelines. Due to increased plasma volume and renal clearance during pregnancy, effectiveness may be reduced; monitor response and adjust dose as needed, but avoid excessive hypotension. Use lowest effective dose.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Minoxidil extra strength (5%) is a topical vasodilator used for androgenetic alopecia. Onset of hair regrowth typically requires 4-6 months of twice-daily application. Initial shedding of telogen hairs may occur in the first 2-6 weeks due to synchronization of hair cycle. Use in patients with cardiovascular disease or those on antihypertensives may theoretically cause systemic effects but is rare at topical doses. Avoid concomitant use with other topical agents that may irritate scalp. Discontinue if no response after 12 months.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Apply 1 m L to dry scalp twice daily, spreading evenly over affected areas.,Wash hands thoroughly after application to avoid unwanted hair growth.,Initial hair shedding is normal and indicates drug is working; do not stop.,Visible results may take 4-6 months; treatment is lifelong to maintain benefits.,Avoid contact with eyes, mouth, and broken skin; if contact occurs, rinse with water.,Do not use more than directed; systemic side effects are rare but include dizziness and rapid heartbeat.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
"Isocarboxazid, a monoamine oxidase inhibitor (MAOI), increases the risk of severe hypotension when combined with minoxidil, a direct-acting vasodilator used for hypertension. The MAOI potentiates the hypotensive effects of minoxidil by inhibiting the metabolism of norepinephrine and other vasoactive amines, leading to exaggerated vasodilation and blood pressure reduction. Clinically, this can result in symptomatic hypotension, dizziness, syncope, and potentially cardiovascular collapse."
"Morphine and minoxidil coadministration can lead to additive hypotensive effects, increasing the risk of severe orthostatic hypotension and syncope. Morphine's vasodilatory properties via histamine release and opioid-induced reduction in sympathetic tone synergize with minoxidil's direct arterial vasodilation, potentially causing a precipitous drop in blood pressure. This interaction is particularly concerning in patients with compromised cardiovascular function or volume depletion, and may necessitate dose adjustments or avoidance."
"Minoxidil, a potent arterial vasodilator used in hypertension and alopecia, can enhance the hypotensive effects of epoprostenol, a prostacyclin analog that directly dilates pulmonary and systemic arteries. The combined vasodilatory action may lead to additive reductions in systemic blood pressure, potentially causing hypotension, dizziness, or syncope, especially during intravenous epoprostenol infusion for pulmonary arterial hypertension. Clinical outcomes may include orthostatic hypotension, reflex tachycardia, and compromised organ perfusion if doses are not adjusted."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINOXIDIL EXTRA STRENGTH (FOR MEN) vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
MINOXIDIL EXTRA STRENGTH (FOR MEN) is a Vasodilator / Hair Growth Stimulant that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINOXIDIL EXTRA STRENGTH (FOR MEN) and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINOXIDIL EXTRA STRENGTH (FOR MEN) is: Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINOXIDIL EXTRA STRENGTH (FOR MEN) and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINOXIDIL EXTRA STRENGTH (FOR MEN) is classified as Category A/B. Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimes. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.